Afuco™ Anti-IGF1R ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-078) (CAT#: AFC-TAB-078)

Add to basket Submit an inquiry form Compare

• Gene Expression
• Datasheet
• MSDS
• COA

Normal Tissue

Figure 1 Cerebral cortex
(Endothelial cells
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Glial cells
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Neuronal cells
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous
Neuropil
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_B_7_5.jpg

Figure 2 Colon
(Endothelial cells
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Glandular cells
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_A_7_3.jpg

Figure 3 Liver
(Cholangiocytes
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Hepatocytes
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_A_8_4.jpg

Figure 4 Kidney
(Cells in glomeruli
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Cells in tubules
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_A_7_5.jpg

Figure 5 Testis
(Cells in seminiferous ducts
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous
Leydig cells
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_A_6_6.jpg

Figure 6 Heart muscle
(Cardiomyocytes
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_B_5_6.jpg

Figure 7 Lymph node
(Germinal center cells
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous
Non-germinal center cells
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/10268/32662_A_7_8.jpg

RNA Expression

Figure 8 RNA cell line category: Low cell line specificity
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000140443-IGF1R

Figure 8 RNA cell line category: Low cell line specificity
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000140443-IGF1R

 Datasheet

 MSDS

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Specifications

Product Property

Target

Related Resources

Insulin Signaling Pathway

Endocrine Resistance

Type I Diabetes Mellitus

Product Notes

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Cixutumumab"

Anti-Human IGF1 Receptor Recombinant Antibody (Cixutumumab)

Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.

DrugMonitor™ Anti-Cixutumumab Antibody (VS-1224-YC284)

Cixutumumab has been evaluated in clinical trials for treating lung cancer, malignant neoplasms, leukemia, mast-cell neoplasms, non-small-cell lung carcinoma, and adenocarcinoma of the prostate, known for its high affinity for the insulin-like growth factor-I receptor (IGF-IR) overexpressed in various tumors. The DrugMonitor™ Anti-Cixutumumab Antibody (VS-1224-YC284) is an anti-drug antibody (ADA) against Cixutumumab. This drug-based antibody is raised in mice immunized with the Cixutumumab. The anti-Cixutumumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Cixutumumab in samples.

See other products for "IGF1R"

Customer Reviews and Q&As

Popular products with customers

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.